#mrna (1 Posts)
-
Moderna's Q4 Results Exceed Expectations, Boosted by Deferred Revenue and Prospects of RSV Vaccine Approval Moderna (MRNA) has released its fourth quarter reports for last year, exceeding market expectations. Moderna’s fourth quarter revenue was $2.81 billion, a 44.7% decrease compared to the previous year, and the adjusted earnings per share (EPS) was $0.55, an 84.8% decrease from the last year. Despite these, the company successfully did a turnaround against the […]
Hot Topics